Effect of IL17 Inhibitor in Comparison With Anti-TNF in Patients With Ankylosing Spondylitis

Launched by SOHAG UNIVERSITY · Oct 11, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the effectiveness of a new treatment called IL-17 inhibitors compared to an existing treatment known as anti-TNF for patients with ankylosing spondylitis (AS). AS is a long-term condition that causes inflammation in the spine and other joints, leading to pain and stiffness. The study aims to see how well these two types of treatments work for people who haven't found relief with standard medications.

To participate in this trial, individuals must be at least 16 years old and have been diagnosed with axial spondyloarthritis for more than six months. They should have tried traditional treatments without success. Participants will be closely monitored and asked to share their experiences with both treatments. It's important to note that this trial is currently recruiting participants of all genders, and those interested should be willing to provide informed consent and answer questions about their health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients fulfill the Assessment in Spondyloarthritis International Society (ASAS) classification criteria for Axial Spondyloarthritis.
• • Patients with disease duration more than 6 months.
• • Patients who failed conventional treatment and on bDMARDs (IL17 or Anti-TNF-α).
• • Age above 16 years old.
• • Patient cooperative and can answer questions.
• • Patients who are able and willing to give written informed consent.
• Exclusion Criteria:
• • Other rheumatologic or collagen diseases.
• • Age below 16 years and above 60 years.
• • Uncooperative patients.
• • Patient not able and willing to give written informed consent.
• • Patient with other causes of platelet dysfunction, count irregularity.